======= WEE1 =======
== Gene Information ==
* **Official Symbol**: WEE1
* **Official Name**: WEE1 G2 checkpoint kinase
* **Aliases and Previous Symbols**: N/A
* **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=7465|7465]]
* **UniProt**: [[https://www.uniprot.org/uniprot/P30291|P30291]]
* **Interactions**: [[https://thebiogrid.org/search.php?search=WEE1&organism=9606|BioGRID]]
* **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20WEE1|Open PubMed]]
* **OMIM**: [[https://omim.org/entry/193525|Open OMIM]]
== Function Summary ==
* **Entrez Summary**: N/A
* **UniProt Summary**: Acts as a negative regulator of entry into mitosis (G2 to M transition) by protecting the nucleus from cytoplasmically activated cyclin B1-complexed CDK1 before the onset of mitosis by mediating phosphorylation of CDK1 on 'Tyr-15'. Specifically phosphorylates and inactivates cyclin B1-complexed CDK1 reaching a maximum during G2 phase and a minimum as cells enter M phase. Phosphorylation of cyclin B1-CDK1 occurs exclusively on 'Tyr-15' and phosphorylation of monomeric CDK1 does not occur. Its activity increases during S and G2 phases and decreases at M phase when it is hyperphosphorylated. A correlated decrease in protein level occurs at M/G1 phase, probably due to its degradation.
|Pkinase Tyr|
|Pkinase|
|non-membrane spanning protein tyrosine kinase activity|
|kinase activity|
|protein tyrosine kinase activity|
|negative regulation of G1/S transition of mitotic cell cycle|
|negative regulation of cell cycle G1/S phase transition|
|establishment of cell polarity|
|G2/M transition of mitotic cell cycle|
|cell cycle G2/M phase transition|
|peptidyl-tyrosine phosphorylation|
|peptidyl-tyrosine modification|
|regulation of G1/S transition of mitotic cell cycle|
|mitotic cell cycle checkpoint|
|regulation of cell cycle G1/S phase transition|
|cell cycle checkpoint|
|establishment or maintenance of cell polarity|
|negative regulation of mitotic cell cycle phase transition|
|magnesium ion binding|
|negative regulation of cell cycle phase transition|
|protein kinase activity|
|mitotic cell cycle phase transition|
|cell cycle phase transition|
|negative regulation of mitotic cell cycle|
|negative regulation of cell cycle process|
|regulation of mitotic cell cycle phase transition|
|regulation of cell cycle phase transition|
|microtubule cytoskeleton organization|
|neuron projection morphogenesis|
|plasma membrane bounded cell projection morphogenesis|
|cell projection morphogenesis|
|cell division|
|cell part morphogenesis|
|negative regulation of cell cycle|
|mitotic cell cycle process|
|regulation of mitotic cell cycle|
|neuron projection development|
|microtubule-based process|
|mitotic cell cycle|
|cell morphogenesis|
|regulation of cell cycle process|
|neuron development|
|cellular component morphogenesis|
|nucleolus|
|peptidyl-amino acid modification|
|protein phosphorylation|
|cell cycle process|
|neuron differentiation|
|cytoskeleton organization|
|plasma membrane bounded cell projection organization|
|cell projection organization|
|regulation of cell cycle|
|phosphorylation|
|cell cycle|
|ATP binding|
|generation of neurons|
|neurogenesis|
|cell development|
\\
=== CRISPR Data ===
^Screen^Score^
|[[:results:exp75|MK-1775 0.32μM R02 exp75]]|-3.31|
|[[:results:exp452|Azithromycin 100μM R08 exp452]]|-2.67|
|[[:results:exp329|Hydroxyurea 100μM R07 exp329]]|-2.34|
|[[:results:exp508|NN-Dimethylsphingosine 2.5μM R08 exp508]]|-2.1|
|[[:results:exp78|Pterostilbene 16μM R02 exp78]]|-2.09|
|[[:results:exp259|6-Thio-2-deoxyguanosine 2μM R06 exp259]]|-2.07|
|[[:results:exp498|Lead acetate 2000μM R08 exp498 no dilution day6]]|-1.93|
|[[:results:exp451|Atovaquone 15μM R08 exp451]]|-1.88|
|[[:results:exp335|Aminopterin 0.005μM R07 exp335]]|-1.87|
|[[:results:exp407|Thapsigargin 0.005μM R07 exp407]]|-1.83|
|[[:results:exp82|Torin1 0.08μM R02 exp82]]|-1.72|
|[[:results:exp524|Staurosporine 0.02μM R08 exp524]]|-1.71|
|[[:results:exp481|Ethambutol 25μM R08 exp481]]|1.71|
|[[:results:exp100|NFN1 1μM R03 exp100]]|1.72|
|[[:results:exp32|Rifampicin 10μM R00 exp32]]|1.72|
|[[:results:exp478|Doxorubicin 0.02μM R08 exp478]]|1.73|
|[[:results:exp273|Cisplatin 0.35μM R06 exp273]]|1.78|
|[[:results:exp131|L-74142 5μM R03 exp131]]|1.8|
|[[:results:exp99|NFN1 0.4μM R03 exp99]]|1.8|
|[[:results:exp294|Nutlin-3A 1.6μM R06 exp294]]|1.81|
|[[:results:exp351|Dexamethasone 0.006μM R07 exp351]]|1.83|
|[[:results:exp372|Ibrutinib 1μM R07 exp372]]|1.84|
|[[:results:exp222|Betulinic acid 10 to 15μM on day4 R05 exp222]]|1.87|
|[[:results:exp310|2-Methoxyestradiol 0.55μM R07 exp310]]|1.9|
|[[:results:exp103|Taxol 0.004μM R03 exp103]]|1.97|
|[[:results:exp249|Vinorelbine 0.001μM R05 exp249]]|2.08|
|[[:results:exp16|DABN 2μM R00 exp16]]|2.15|
|[[:results:exp12|Chloramphenicol 2μM R00 exp12]]|2.19|
|[[:results:exp311|2-Methoxyestradiol 0.55 to 0.75μM on day4 R07 exp311]]|2.21|
|[[:results:exp494|Isoniazid 100μM R08 exp494]]|2.22|
|[[:results:exp278|CVT-10216 0.1μM R06 exp278]]|2.54|
|[[:results:exp29|Rapamycin 1μM R00 exp29]]|2.79|
|[[:results:exp1|5-Fluorouracil 2μM R00 exp1]]|2.97|
|[[:results:exp11|CCCP 1μM R00 exp11]]|3.72|
|[[:results:exp198|Etoposide 0.1μM R05 exp198]]|4.63|
^Gene^Correlation^
|[[:human genes:p:polr2j3|POLR2J3]]|0.421|
Global Fraction of Cell Lines Where Essential: 739/739
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|1/1|
|909776.0|1/1|
|bile duct|28/28|
|blood|28/28|
|bone|26/26|
|breast|33/33|
|central nervous system|56/56|
|cervix|4/4|
|colorectal|17/17|
|esophagus|13/13|
|fibroblast|1/1|
|gastric|16/16|
|kidney|21/21|
|liver|20/20|
|lung|75/75|
|lymphocyte|16/16|
|ovary|26/26|
|pancreas|24/24|
|peripheral nervous system|16/16|
|plasma cell|15/15|
|prostate|1/1|
|skin|24/24|
|soft tissue|9/9|
|thyroid|2/2|
|upper aerodigestive|22/22|
|urinary tract|29/29|
|uterus|5/5|
== Essentiality in NALM6 ==
* **Essentiality Rank**: 756
* **Expression level (log2 read counts)**: 7.1
{{:chemogenomics:nalm6 dist.png?nolink |}}